Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

35 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Optimal treatment of metastatic colorectal cancer.
Pessino A, Sobrero A. Pessino A, et al. Expert Rev Anticancer Ther. 2006 May;6(5):801-12. doi: 10.1586/14737140.6.5.801. Expert Rev Anticancer Ther. 2006. PMID: 16759170 Review.
Recently, a new orally active fluorouracil analog, capecitabine, and two targeted biological agents, cetuximab and bevacizumab, have been added to the armamentarium of drugs active against metastatic colorectal cancer, thus making the scenario more complex. ...Thus, we are …
Recently, a new orally active fluorouracil analog, capecitabine, and two targeted biological agents, cetuximab and bevacizumab, have …
First-line single-agent cetuximab in patients with advanced colorectal cancer.
Pessino A, Artale S, Sciallero S, Guglielmi A, Fornarini G, Andreotti IC, Mammoliti S, Comandini D, Caprioni F, Bennicelli E, Andretta V, Siena S, Sobrero A. Pessino A, et al. Ann Oncol. 2008 Apr;19(4):711-6. doi: 10.1093/annonc/mdm516. Epub 2007 Dec 10. Ann Oncol. 2008. PMID: 18073221 Clinical Trial.
One patient had a complete response and three obtained partial responses (10% overall response rate). Thirteen patients had stable disease (34%). ...CONCLUSIONS: Even in chemo-naive patients, cetuximab as single agent is active only in a small fraction of mCRC, simi …
One patient had a complete response and three obtained partial responses (10% overall response rate). Thirteen patients had stable di …
Two doses of NGR-hTNF in combination with capecitabine plus oxaliplatin in colorectal cancer patients failing standard therapies.
Mammoliti S, Andretta V, Bennicelli E, Caprioni F, Comandini D, Fornarini G, Guglielmi A, Pessino A, Sciallero S, Sobrero AF, Mazzola G, Lambiase A, Bordignon C. Mammoliti S, et al. Among authors: pessino a. Ann Oncol. 2011 Apr;22(4):973-978. doi: 10.1093/annonc/mdq436. Epub 2010 Sep 20. Ann Oncol. 2011. PMID: 20855468 Free PMC article. Clinical Trial.
Phase II study of NGR-hTNF, a selective vascular targeting agent, in patients with metastatic colorectal cancer after failure of standard therapy.
Santoro A, Rimassa L, Sobrero AF, Citterio G, Sclafani F, Carnaghi C, Pessino A, Caprioni F, Andretta V, Tronconi MC, Finocchiaro G, Rossoni G, Zanoni A, Miggiano C, Rizzardi GP, Traversari C, Caligaris-Cappio F, Lambiase A, Bordignon C. Santoro A, et al. Among authors: pessino a. Eur J Cancer. 2010 Oct;46(15):2746-52. doi: 10.1016/j.ejca.2010.07.012. Epub 2010 Aug 12. Eur J Cancer. 2010. PMID: 20708923 Clinical Trial.
Rasch-built Overall Disability Scale for patients with chemotherapy-induced peripheral neuropathy (CIPN-R-ODS).
Binda D, Vanhoutte EK, Cavaletti G, Cornblath DR, Postma TJ, Frigeni B, Alberti P, Bruna J, Velasco R, Argyriou AA, Kalofonos HP, Psimaras D, Ricard D, Pace A, Galiè E, Briani C, Dalla Torre C, Lalisang RI, Boogerd W, Brandsma D, Koeppen S, Hense J, Storey D, Kerrigan S, Schenone A, Fabbri S, Rossi E, Valsecchi MG, Faber CG, Merkies IS; CI-PeriNomS study group, Galimberti S, Lanzani F, Mattavelli L, Piatti ML, Bidoli P, Cazzaniga M, Cortinovis D, Lucchetta M, Campagnolo M, Bakkers M, Brouwer B, Boogerd W, Grant R, Reni L, Piras B, Pessino A, Padua L, Granata G, Leandri M, Ghignotti I, Plasmati R, Pastorelli F, Heimans JJ, Eurelings M, Meijer RJ, Grisold W, Lindeck Pozza E, Mazzeo A, Toscano A, Russo M, Tomasello C, Altavilla G, Penas Prado M, Dominguez Gonzalez C, Dorsey SG. Binda D, et al. Among authors: pessino a. Eur J Cancer. 2013 Sep;49(13):2910-8. doi: 10.1016/j.ejca.2013.04.004. Epub 2013 May 10. Eur J Cancer. 2013. PMID: 23668917
TLR activation of tumor-associated macrophages from ovarian cancer patients triggers cytolytic activity of NK cells.
Bellora F, Castriconi R, Dondero A, Pessino A, Nencioni A, Liggieri G, Moretta L, Mantovani A, Moretta A, Bottino C. Bellora F, et al. Among authors: pessino a. Eur J Immunol. 2014 Jun;44(6):1814-22. doi: 10.1002/eji.201344130. Epub 2014 Mar 6. Eur J Immunol. 2014. PMID: 24510590 Free article. Clinical Trial.
Ambulatory blood pressure is superior to clinic blood pressure in predicting treatment-induced regression of left ventricular hypertrophy. SAMPLE Study Group. Study on Ambulatory Monitoring of Blood Pressure and Lisinopril Evaluation.
Mancia G, Zanchetti A, Agabiti-Rosei E, Benemio G, De Cesaris R, Fogari R, Pessina A, Porcellati C, Rappelli A, Salvetti A, Trimarco B. Mancia G, et al. Circulation. 1997 Mar 18;95(6):1464-70. doi: 10.1161/01.cir.95.6.1464. Circulation. 1997. PMID: 9118514 Clinical Trial.
Before treatment, LVMI did not correlate with clinic BP, but it showed a correlation with systolic and diastolic 24-hour average BP (r = .34/.27, P < .01). ...
Before treatment, LVMI did not correlate with clinic BP, but it showed a correlation with systolic and diastolic 24-hour average BP ( …
An Historical Overview: The Discovery of How NK Cells Can Kill Enemies, Recruit Defense Troops, and More.
Vitale M, Cantoni C, Della Chiesa M, Ferlazzo G, Carlomagno S, Pende D, Falco M, Pessino A, Muccio L, De Maria A, Marcenaro E, Moretta L, Sivori S. Vitale M, et al. Among authors: pessino a. Front Immunol. 2019 Jun 19;10:1415. doi: 10.3389/fimmu.2019.01415. eCollection 2019. Front Immunol. 2019. PMID: 31316503 Free PMC article. Review.
Patients' and physicians' interpretation of chemotherapy-induced peripheral neurotoxicity.
Cavaletti G, Cornblath DR, Merkies ISJ, Postma TJ, Rossi E, Alberti P, Bruna J, Argyriou AA, Briani C, Velasco R, Kalofonos HP, Psimaras D, Ricard D, Pace A, Faber CG, Lalisang RI, Brandsma D, Koeppen S, Kerrigan S, Schenone A, Grisold W, Mazzeo A, Padua L, Dorsey SG, Penas-Prado M, Valsecchi MG; CI-PeriNomS Group. Cavaletti G, et al. J Peripher Nerv Syst. 2019 Mar;24(1):111-119. doi: 10.1111/jns.12306. Epub 2019 Feb 8. J Peripher Nerv Syst. 2019. PMID: 30672664
Evaluation of the psychometric properties of the EORTC chemotherapy-induced peripheral neuropathy questionnaire (QLQ-CIPN20).
Kieffer JM, Postma TJ, van de Poll-Franse L, Mols F, Heimans JJ, Cavaletti G, Aaronson NK; CI-PeriNomS Group. Kieffer JM, et al. Qual Life Res. 2017 Nov;26(11):2999-3010. doi: 10.1007/s11136-017-1626-1. Epub 2017 Jun 20. Qual Life Res. 2017. PMID: 28634676
35 results
Jump to page
Feedback